Organ Transplant Tolerance: Strategies for Immune Acceptance

Goal

Achieve donor-specific immune tolerance so the recipient's immune system accepts the graft without lifelong broad immunosuppression.

Current Mainstay: Immunosuppressive Drugs

  • Calcineurin inhibitors: Tacrolimus, cyclosporine.
  • Antiproliferatives: Mycophenolate mofetil, azathioprine.
  • Corticosteroids: Prednisone.
  • mTOR inhibitors: Sirolimus, everolimus.
  • Costimulation blocker: Belatacept (CTLA-4-Ig).

Combination regimens balance efficacy and toxicity.

Emerging Tolerance-Induction Approaches

1. Mixed Chimerism

Co-transplantation of donor hematopoietic stem cells creates a chimeric immune system that recognizes the graft as self. Used in some kidney transplant protocols.

2. Costimulation Blockade

Agents like belatacept (blocks CD28-CD80/86) and abatacept prevent full T-cell activation, promoting anergy.

3. T-Cell Depletion

Anti-thymocyte globulin or alemtuzumab deplete recipient T cells pre-transplant, reducing alloreactive clones.

4. Regulatory T-Cell (Treg) Therapy

Ex vivo expanded autologous or donor Tregs infused post-transplant to actively suppress rejection.

5. Tolerogenic Dendritic Cells

Donor-derived DCs treated to induce antigen-specific tolerance.

Challenges

  • Protocol complexity and cost.
  • Risk of infection, malignancy, and drug toxicity during transition.
  • Need for reliable biomarkers to confirm true tolerance.

Ongoing clinical trials aim to make tolerance induction safer and more widely applicable.

Kidney Disease - Related Articles